{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-039883","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.987084+00:00","generated_at":"2026-05-17T14:24:30.294017+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Zevra Q2 net revenue $25.9M, net income $74.7M on PRV sale; adjusted net loss $3.2M","bullets":["Product net revenue $21.8M (MIPLYFFA $21.5M, OLPRUVA $0.3M) vs $4.4M total revenue in Q2 2024.","Closed sale of PRV for $150.0M on April 1, boosting cash to $217.7M as of June 30.","Non-cash impairment of OLPRUVA intangible assets $58.7M and inventory obsolescence $11.7M.","Adjusted net loss $(3.2)M ($(0.06)/share) excluding PRV sale and impairment charges.","MIPLYFFA launch: 7 new enrollment forms in Q2, total 129 since launch; market access 52%."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-039883","json":"https://secwatch.observer/filing/0001628280-25-039883.json","markdown":"https://secwatch.observer/filing/0001628280-25-039883.md","text":"https://secwatch.observer/filing/0001628280-25-039883.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000162828025039883/0001628280-25-039883-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000162828025039883/zvra-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:24:30.294017+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}